MTOR and tuberous sclerosis: iPSCs can be derived from TSC patient somatic cells and differentiated into tissue-specific derivatives to model the development of different organs impacted by TSC and trial therapeutic agents e.g. mTOR inhibitors as a preventative measure that may alter disease progression [59, 60].